These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6513814)

  • 1. Restoration by MDP-Lys (L18) of resistance to Pseudomonas pneumonia in immunosuppressed guinea pigs.
    Otani T; Katami K; Une T; Osada Y; Ogawa H
    Microbiol Immunol; 1984; 28(9):1077-82. PubMed ID: 6513814
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of non-specific resistance to Pseudomonas pneumonia by a synthetic derivative of muramoyl dipeptide in immunosuppressed guinea pigs.
    Osada Y; Ohtani T; Une T; Ogawa H; Nomoto K
    J Gen Microbiol; 1982 Oct; 128(10):2361-70. PubMed ID: 7153754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
    Ishihara C; Yamamoto K; Hamada N; Azuma I
    Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
    Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs 1, 2.
    Kamisango K; Saiki I; Tanio Y; Kobayashi S; Fukuda T; Sekikawa I; Azuma I; Yamamura Y
    Chem Pharm Bull (Tokyo); 1981 Jun; 29(6):1644-54. PubMed ID: 7296716
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro and in vivo effects of MDP-Lys(L18) on mouse megakaryocyte progenitor cells (CFU-Meg).
    Komiya I; Kuriya S; Akahane K; Nomura T
    Exp Hematol; 1992 May; 20(4):517-22. PubMed ID: 1568468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
    Ishihara C; Mizukoshi N; Iida J; Kato K; Yamamoto K; Azuma I
    Vaccine; 1987 Dec; 5(4):295-301. PubMed ID: 2448969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher immunoadjuvant activities of N-acetyl-beta-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine in comparison with N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Tsujimoto M; Kinoshita F; Okunaga T; Kotani S; Kusumoto S; Yamamoto K; Shiba T
    Microbiol Immunol; 1979; 23(9):933-6. PubMed ID: 576117
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.
    Parant M; Chedid L
    Infection; 1984; 12(3):230-4. PubMed ID: 6469369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Nagao S; Sato K; Osada Y
    Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.